Hepatitis Monthly

Published by: Kowsar

Molecular Characterization of Drug Resistance in Hepatitis B Viruses Isolated from Patients with Chronical Infection in Turkey

Ali Asan 1 , * , Murat Sayan 2 , 3 , Sila Akhan 4 , Suda Tekin Koruk 5 , Bilgehan Aygen 6 , Fatma Sirmatel 7 , Haluk Eraksoy 8 , Nazan Tuna 9 , Sukran Köse 10 , Ali Kaya 11 , Necla Eren Tulek 12 , Nazlim Aktug Demir 13 , Resit Mistik 14 , Bahar Ormen 15 , Fatime Korkmaz 16 , Taner Yildirmak 17 , Onur Ural 13 , Mehtap Aydin 18 , Huseyin Turgut 19 , Ozgur Gunal 20 and Nese Demirturk 21
Authors Information
1 Department of Infectious Diseases and Clinical Microbiology, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey
2 Kocaeli University Faculty of Medicine, PCR Unit, Clinical Laboratory, Kocaeli, Turkey
3 Research Center of Experimental Health Sciences, Near East University, Nicosia, Northern Cyprus
4 Department of Infectious Diseases and Clinical Microbiology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey
5 Department of Infectious Diseases and Clinical Microbiology, Koc University Faculty of Medicine, Istanbul, Turkey
6 Department of Infectious Diseases and Clinical Microbiology, Erciyes University Faculty of Medicine, Kayseri, Turkey
7 Department of Infectious Diseases and Clinical Microbiology, Abant Izzet Baysal University Faculty of Medicine, Bolu, Turkey
8 Department of Infectious Disease and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
9 Department of Infectious Diseases and Clinical Microbiology, Sakarya University Faculty of Medicine, Sakarya, Turkey
10 Department of Infectious Diseases and Clinical Microbiology, Tepecik Training and Research Hospital, Izmir, Turkey
11 Department of Infectious Diseases and Clinical Microbiology, Mersin University Faculty of Medicine, Mersin, Turkey
12 Department of Infectious Diseases and Clinical Microbiology, Ankara Training and Research Hospital, Ankara, Turkey
13 Department of Infectious Diseases and Clinical Microbiology, Selcuk University Faculty of Medicine, Konya, Turkey
14 Department of Infectious Diseases and Clinical Microbiology, Uludag University Faculty of Medicine, Bursa, Turkey
15 Department of Infectious Diseases and Clinical Microbiology, Izmir Katip Celebi University Atatürk Training and Research Hospital, Izmir, Turkey
16 Department of Infectious Diseases and Clinical Microbiology, Konya Training and Research Hospital, Konya, Turkey
17 Department of Infectious Diseases and Clinical Microbiology, Okmeydani Training and Research Hospital, Istanbul, Turkey
18 Department of Infectious Disease and Clinical Microbiology, Baskent University Faculty of Medicine, Istanbul, Turkey
19 Department of Infectious Diseases and Clinical Microbiology, Pamukkale University Faculty of Medicine, Denizli, Turkey
20 Department of Infectious Diseases and Clinical Microbiology, Samsun Training and Research Hospital, Samsun, Turkey
21 Department of Infectious Diseases and Clinical Microbiology, Kocatepe University Faculty of Medicine, Afyon, Turkey
Article information
  • Hepatitis Monthly: January 2018, 18 (1); e12472
  • Published Online: January 24, 2018
  • Article Type: Research Article
  • Received: May 3, 2017
  • Revised: November 10, 2017
  • Accepted: December 28, 2017
  • DOI: 10.5812/hepatmon.12472

To Cite: Asan A, Sayan M, Akhan S, Tekin Koruk S, Aygen B, et al. Molecular Characterization of Drug Resistance in Hepatitis B Viruses Isolated from Patients with Chronical Infection in Turkey, Hepat Mon. 2018 ;18(1):e12472. doi: 10.5812/hepatmon.12472.

Abstract
Copyright © 2018, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
References
  • 1. Miller RH, Kaneko S, Chung CT, Girones R, Purcell RH. Compact organization of the hepatitis B virus genome. Hepatology. 1989;9(2):322-7. [PubMed: 2643549].
  • 2. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini SA, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology. 2002;293(2):305-13. doi: 10.1006/viro.2001.1246. [PubMed: 11886250].
  • 3. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology. 2006;44(6):1656-65. doi: 10.1002/hep.21422. [PubMed: 17133475].
  • 4. Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol. 2008;48 Suppl 1:S2-19. doi: 10.1016/j.jhep.2008.01.011. [PubMed: 18304680].
  • 5. Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int. 2008;2(2):147-51. doi: 10.1007/s12072-008-9048-3. [PubMed: 19669299].
  • 6. Mistik R. Turkiye de viral hepatit epidemiyolojisi yayinlarin irdelenmesi, Yayinların irdelenmesi. In: Tabak, F , Balik, İ , Tekeli, E , editors. Viral hepatit. 1. Istanbul: VHSD; 2007. p. 10-50.
  • 7. Gurol E, Saban C, Oral O, Cigdem A, Armagan A. Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey. Eur J Epidemiol. 2006;21(4):299-305. doi: 10.1007/s10654-006-0001-2. [PubMed: 16685581].
  • 8. Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21(11):1020-6. doi: 10.1016/j.cmi.2015.06.028. [PubMed: 26163105].
  • 9. Toy M, Onder FO, Wormann T, Bozdayi AM, Schalm SW, Borsboom GJ, et al. Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review. BMC Infect Dis. 2011;11:337. doi: 10.1186/1471-2334-11-337. [PubMed: 22151620].
  • 10. European Association For The Study Of The L. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167-85. doi: 10.1016/j.jhep.2012.02.010. [PubMed: 22436845].
  • 11. Sayan M, Akhan SC, Meric M. Naturally occurring amino-acid substitutions to nucleos(t)ide analogues in treatment naive Turkish patients with chronic hepatitis B. J Viral Hepat. 2010;17(1):23-7. doi: 10.1111/j.1365-2893.2009.01149.x. [PubMed: 19566788].
  • 12. Papatheodoridis GV, Deutsch M. Resistance issues in treating chronic hepatitis B. Future Microbiol. 2008;3(5):525-38. doi: 10.2217/17460913.3.5.525. [PubMed: 18811237].
  • 13. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol. 2006;44(3):593-606. doi: 10.1016/j.jhep.2006.01.001. [PubMed: 16455151].
  • 14. Sheldon J, Rodes B, Zoulim F, Bartholomeusz A, Soriano V. Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat. 2006;13(7):427-34. doi: 10.1111/j.1365-2893.2005.00713.x. [PubMed: 16792535].
  • 15. Avellon A, Echevarria JM. Frequency of hepatitis B virus 'a' determinant variants in unselected Spanish chronic carriers. J Med Virol. 2006;78(1):24-36. doi: 10.1002/jmv.20516. [PubMed: 16299725].
  • 16. Locarnini S, Bowden S. Drug resistance in antiviral therapy. Clin Liver Dis. 2010;14(3):439-59. doi: 10.1016/j.cld.2010.05.004. [PubMed: 20638024].
  • 17. Sheldon J, Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother. 2008;61(4):766-8. doi: 10.1093/jac/dkn014. [PubMed: 18218641].
  • 18. Teo CG, Locarnini SA. Potential threat of drug-resistant and vaccine-escape HBV mutants to public health. Antivir Ther. 2010;15(3 Pt B):445-9. doi: 10.3851/IMP1556. [PubMed: 20516564].
  • 19. Locarnini SA, Yuen L. Molecular genesis of drug-resistant and vaccine-escape HBV mutants. Antivir Ther. 2010;15(3 Pt B):451-61. doi: 10.3851/IMP1499. [PubMed: 20516565].
  • 20. Sayan M, Cavdar C, Dogan C. Naturally occurring polymerase and surface gene variants of hepatitis B virus in Turkish hemodialysis patients with chronic hepatitis B. Jpn J Infect Dis. 2012;65(6):495-501. [PubMed: 23183201].
  • 21. Vutien P, Trinh HN, Garcia RT, Nguyen HA, Levitt BS, Nguyen K, et al. Mutations in HBV DNA polymerase associated with nucleos(t)ide resistance are rare in treatment-naive patients. Clin Gastroenterol Hepatol. 2014;12(8):1363-70. doi: 10.1016/j.cgh.2013.11.036. [PubMed: 24342744].
  • 22. Han Y, Huang LH, Liu CM, Yang S, Li J, Lin ZM, et al. Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients. J Gastroenterol Hepatol. 2009;24(8):1417-23. doi: 10.1111/j.1440-1746.2009.05864.x. [PubMed: 19486254].
  • 23. Jardi R, Rodriguez-Frias F, Buti M, Schaper M, Esteban R, Guardia J. Mutations at HBV-polymerase gene associated with entecavir drug resistance in patients not undergoing entecavir therapy. Hepatol. 2006;44:547A.
  • 24. Lampertico P, Viganò M, Facchetti F, Puoti M, Minola E, Suter F, et al. Effectiveness of entecavir for the treatment of NUC-naive chronic hepatitis B patients: a large multicenter cohort study in clinical practice. Hepatol. 2008;48(Suppl 1):707A-8A.
  • 25. Ludwig AD, Goebel T, Adams O, Baumann N, Hauck K, Fey H, et al. Primary resistance mutations against nucleos (t) ide analogues in treatment name patients with hbv-infection. Hepatol. 2008;48(4):701A.
  • 26. Mirandola S, Campagnolo D, Bortoletto G, Franceschini L, Marcolongo M, Alberti A. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B. J Viral Hepat. 2011;18(7):212-6. doi: 10.1111/j.1365-2893.2011.01435.x. [PubMed: 21692935].
  • 27. Salpini R, Svicher V, Cento V, Gori C, Bertoli A, Scopelliti F, et al. Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naive to antiviral drugs. Antiviral Res. 2011;92(2):382-5. doi: 10.1016/j.antiviral.2011.08.013. [PubMed: 21920388].
  • 28. Ergunay K, Kahramanoglu Aksoy E, Simsek H, Alp A, Sener B, Tatar G, et al. [Investigation of baseline antiviral resistance in treatment-naive chronic hepatitis B cases]. Mikrobiyol Bul. 2013;47(4):628-35. [PubMed: 24237431].
  • 29. Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis. 2006;26(2):162-70. doi: 10.1055/s-2006-939758. [PubMed: 16673294].
  • 30. Sayan M, Akhan SC, Senturk O. Frequency and mutation patterns of resistance in patients with chronic hepatitis B infection treated with nucleos(t)ide analogs in add-on and switch strategies. Hepat Mon. 2011;11(10):835-42. doi: 10.5812/kowsar.1735143X.775. [PubMed: 22224083].
  • 31. Liu Y, Wang CM, Cheng J, Liang ZL, Zhong YW, Ren XQ, et al. Hepatitis B virus in tenofovir-naive Chinese patients with chronic hepatitis B contains no mutation of rtA194T conferring a reduced tenofovir susceptibility. Chin Med J (Engl). 2009;122(13):1585-6. [PubMed: 19719953].
  • 32. Xu Y, Zhang YG, Wang X, Qi WQ, Qin SY, Liu ZH, et al. Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis. World J Gastroenterol. 2015;21(25):7869-76. doi: 10.3748/wjg.v21.i25.7869. [PubMed: 26167087].
  • 33. Osiowy C, Villeneuve JP, Heathcote EJ, Giles E, Borlang J. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J Clin Microbiol. 2006;44(6):1994-7. doi: 10.1128/JCM.02477-05. [PubMed: 16757589].
  • 34. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatol. 2007;46(1):254-65. doi: 10.1002/hep.21698. [PubMed: 17596850].
  • 35. Amini-Bavil-Olyaee S, Herbers U, Mohebbi SR, Sabahi F, Zali MR, Luedde T, et al. Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome. J Hepatol. 2009;51(4):647-54. doi: 10.1016/j.jhep.2009.04.022. [PubMed: 19586679].
  • 36. Sayan M, Akhan SC. Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B. Int J Infect Dis. 2011;15(10):722-6. doi: 10.1016/j.ijid.2011.05.019. [PubMed: 21784687].
  • 37. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatol. 2008;48(1):88-98. doi: 10.1002/hep.22295. [PubMed: 18537180].
  • 38. Clements CJ, Coghlan B, Creati M, Locarnini S, Tedder RS, Torresi J. Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization?. Bull World Health Organ. 2010;88(1):66-73. doi: 10.2471/BLT.08.065722. [PubMed: 20428355].
  • 39. Locarnini S. Transmission of antiviral drug resistant hepatitis B virus: implications for public health and patient management. J Gastroenterol Hepatol. 2010;25(4):649-51. doi: 10.1111/j.1440-1746.2010.06255.x. [PubMed: 20492319].
  • 40. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol. 2002;25(2):97-106. [PubMed: 12367644].
  • 41. Sayan M, Senturk O, Akhan SC, Hulagu S, Cekmen MB. Monitoring of hepatitis B virus surface antigen escape mutations and concomitantly nucleos(t)ide analog resistance mutations in Turkish patients with chronic hepatitis B. Int J Infect Dis. 2010;14 Suppl 3:136-41. doi: 10.1016/j.ijid.2009.11.039. [PubMed: 20382061].
  • 42. Hadziyannis SJ. Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol. 2011;55(1):183-91. doi: 10.1016/j.jhep.2010.12.030. [PubMed: 21238520].
  • 43. Sunbul M. Hepatitis B virus genotypes: global distribution and clinical importance. World J Gastroenterol. 2014;20(18):5427-34. doi: 10.3748/wjg.v20.i18.5427. [PubMed: 24833873].
  • 44. Sayan M, Sargin F, Inan D, Sevgi DY, Celikbas AK, Yasar K, et al. HIV-1 Transmitted Drug Resistance Mutations in Newly Diagnosed Antiretroviral-Naive Patients in Turkey. AIDS Res Hum Retroviruses. 2016;32(1):26-31. doi: 10.1089/AID.2015.0110. [PubMed: 26414663].
  • 45. Bagheri Amiri F, Mostafavi E, Mirzazadeh A. HIV, HBV and HCV Coinfection Prevalence in Iran--A Systematic Review and Meta-Analysis. PLoS One. 2016;11(3):151946. doi: 10.1371/journal.pone.0151946. [PubMed: 27031352].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments